Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Overview
Date Founded

2010

Headquarters

10880 WILSHIRE BOULEVARD,, SUITE 2150, LOS ANGELES, CA, 90024

Type of Company

Public

Employees (Worldwide)

269

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Contact Data
Trying to get in touch with decision makers at Puma Biotechnology, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Financial Officer

Chief Commercial Officer

Chief Medical & Scientific Officer

Senior Vice President, Regulatory Affairs, Medical Writing & Project Management

Owner Partner

Owner

Board of Directors

Founder at Puma Biotechnology, Inc.

Chief Financial Officer at Sera Prognostics, Inc.

Co-Founder at Avidity Biosciences LLC

Former Franchise Head at Genentech, Inc.

Former Vice President, Marketing at Sanofi

Former President & Chief Executive Officer at Neon Therapeutics, Inc.

Paths to Puma Biotechnology, Inc.
Potential Connections via
Relationship Science
You
Puma Biotechnology, Inc.
Owners & Shareholders
Details Hidden

Ecor1 Capital manages the EcoR1 Capital Fund LP, a fundamental long/short equity hedge fund focusing on investment opportunities in the biotechnology sector. The firm employs an innovative, process-driven approach that is based on a value philosophy which attempts to manage risk in the volatile biotechnology sector. The fund focuses on outliers not typically analyzed as part of value based diligence; human capital in addition to deep scientific and financial analysis. Ecor1 Capital is committed to going beyond the usual monetary investment in companies and engages directly with management to identify opportunities for efficiencies and growth, and where necessary, invests their own human capital resources to help mediate much of the risk that is inherent in the sector. The goal of combining this innovative perspective and process is generation of uncorrelated returns relative to the biotechnology sector and to the overall market.

Details Hidden

Palo Alto Investors, LLC (PAI) is a leading private investment firm. We make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. We don’t rent stocks. We own them. With approximately $900 million in assets under management, we offer a diversified micro cap fund and healthcare sector funds. Significant partner ownership in all of our Funds serves to align our financial interests with the financial interests of our clients. At PAI our mission is to deliver superior returns to our clients by investing for the long term. At the core of our investment philosophy lies the belief that intensive, original research is required to discover and evaluate inefficiently priced equities. We generally focus our investments in micro cap and small cap U.S. equities, which are not closely followed by Wall Street sell-side research firms. We target overlooked, misunderstood and undervalued segments of the equity markets, such as healthcare, energy and technology that have significant potential for appreciation. Our experienced research team has extensive industry experience in the sectors they cover. They utilize a disciplined, bottom-up approach to identify promising investments, and the firm’s investment policies ensure liquidity horizons that are sufficient to take advantage of new opportunities. PAI is committed to providing exemplary client service, maintaining the highest level of ethics, operational excellence and professionalism. PAI is independently owned, and has been registered with the SEC since its inception in 1989

Details Hidden

Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.

Recent Transactions
Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Auditor

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Managing Director

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Clients

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Cigna Corp. is a global health service company, which is dedicated to improving the health, well-being and peace of mind. Its products and services include an integrated suite of health services such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits and other related products including group life, accident and disability insurance.

Cigna is a global health service company, dedicated to helping the people we serve improve their health, well-being and sense of security. We make this happen through a broad range of integrated health care and related plans and services, and proven health and well-being programs that are targeted to the unique needs of our customers, clients and partners. "At Cigna, we understand that people are unique, and so, too, is their health. In a world of many millions, we see each person defining a healthy life on his or her own terms. It's our aim to be part of that journey, helping people achieve better health and peace of mind along the way." - David Cordani, CEO

Key Stats and Financials As of 2019
Market Capitalization
$498M
Total Enterprise Value
$339M
Earnings Per Share
$-1.95
Revenue
$272M
Net Profit
$-75.6M
EBITDA
$-31M
EBITDAMargin
-11.39%
Total Debt
$120M
Total Equity
$17.5M
Enterprise Value Sales
1.25x
TEVNet Income
-4.48x
Debt TEV
0.35x
Non-Profit Donations & Grants
$5,000 - $10K
2018
Investors
Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR's or its affiliates' central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

OrbiMed focuses exclusively on global investments across the entire spectrum of private and publicly-traded life sciences companies. They seek to invest in the most promising investment opportunities regardless of a company's stage of development. The firm invests at all stages of development from private start-ups and university spinouts to the largest global pharmaceutical companies. OrbiMed focuses on companies involved in drug development, drug discovery and medical devices, with particular emphasis on mid-stage private companies. Investments typically range from $5 million to $40 million. OrbiMed is generally a lead investor and takes an active role on their portfolio companies' boards of directors

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

CaligorRx, Inc. Medical Products & Equipment | Secaucus, NJ

Caligor RX, Inc. provides clinical trial supply and logistics services. It manages the regulatory, logistics, and supply chain challenges of sourcing, storing, and distributing investigational drugs for comparator clinical trials and unlicensed medicines for expanded access programs. The firm serves pharmaceutical and biotechnology companies. The company is headquartered in Secaucus, NJ.

Competitors
Seattle Genetics, Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Puma Biotechnology, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Puma Biotechnology, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Puma Biotechnology, Inc..